Croda Showcases High-Purity Pharma Excipients at CPhI Worldwide 2017
Croda is showcasing its portfolio of high-purity pharmaceutical excipients that can be used to maximize API performance.
Croda, a supplier of natural-based specialty chemicals, is showcasing its portfolio of high-purity pharmaceutical excipients that can be used to maximize API performance at CPhI Worldwide 2017. The company has manufacturing facilities around the globe.
Experts from Croda will be available to talk about the benefits of high-purity pharmaceutical ingredients for multiple drug administration routes, including the parenteral, ophthalmic, oral, and topical routes.
Visitor can visit Croda at CPhI to learn more about:
- Improved API stability
- Reduced cellular irritation
- Increased API delivery
- Accelerated speed to market
- Reducing drug development times
- Simplifying formulations
Source: Croda, Stand 102B11
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
